GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (NAS:PMN) » Definitions » Cyclically Adjusted Book per Share

PMN (ProMIS Neurosciences) Cyclically Adjusted Book per Share : $0.09 (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is ProMIS Neurosciences Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

ProMIS Neurosciences's adjusted book value per share for the three months ended in Jun. 2024 was $-0.120. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.09 for the trailing ten years ended in Jun. 2024.

During the past 12 months, ProMIS Neurosciences's average Cyclically Adjusted Book Growth Rate was 50.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -35.90% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -46.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of ProMIS Neurosciences was -33.90% per year. The lowest was -56.30% per year. And the median was -45.15% per year.

As of today (2024-10-09), ProMIS Neurosciences's current stock price is $1.03. ProMIS Neurosciences's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was $0.09. ProMIS Neurosciences's Cyclically Adjusted PB Ratio of today is 11.44.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ProMIS Neurosciences was 12.01. The lowest was 0.49. And the median was 3.18.


ProMIS Neurosciences Cyclically Adjusted Book per Share Historical Data

The historical data trend for ProMIS Neurosciences's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences Cyclically Adjusted Book per Share Chart

ProMIS Neurosciences Annual Data
Trend Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.90 0.38 0.14 0.09 0.10

ProMIS Neurosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.08 0.10 0.10 0.09

Competitive Comparison of ProMIS Neurosciences's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, ProMIS Neurosciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProMIS Neurosciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where ProMIS Neurosciences's Cyclically Adjusted PB Ratio falls into.



ProMIS Neurosciences Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ProMIS Neurosciences's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book= Book Value per Share /CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.12/127.5217*127.5217
=-0.120

Current CPI (Jun. 2024) = 127.5217.

ProMIS Neurosciences Quarterly Data

Book Value per Share CPI Adj_Book
201409 -0.065 99.394 -0.083
201412 0.000 98.367 0.000
201503 -0.428 99.789 -0.547
201506 -0.625 100.500 -0.793
201509 0.319 100.421 0.405
201512 0.169 99.947 0.216
201603 0.176 101.054 0.222
201606 0.104 102.002 0.130
201609 0.275 101.765 0.345
201612 0.017 101.449 0.021
201703 0.370 102.634 0.460
201706 -0.017 103.029 -0.021
201709 0.571 103.345 0.705
201712 0.332 103.345 0.410
201803 0.380 105.004 0.461
201806 1.256 105.557 1.517
201809 0.837 105.636 1.010
201812 0.206 105.399 0.249
201903 0.203 106.979 0.242
201906 0.095 107.690 0.112
201909 -0.166 107.611 -0.197
201912 0.066 107.769 0.078
202003 -0.029 107.927 -0.034
202006 -0.080 108.401 -0.094
202009 -0.316 108.164 -0.373
202012 -0.165 108.559 -0.194
202103 -1.349 110.298 -1.560
202106 -1.392 111.720 -1.589
202109 1.048 112.905 1.184
202112 0.787 113.774 0.882
202203 0.520 117.646 0.564
202206 0.933 120.806 0.985
202209 0.101 120.648 0.107
202212 -0.157 120.964 -0.166
202303 -0.720 122.702 -0.748
202306 -0.994 124.203 -1.021
202309 0.365 125.230 0.372
202312 0.199 125.072 0.203
202403 0.004 126.258 0.004
202406 -0.120 127.522 -0.120

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


ProMIS Neurosciences  (NAS:PMN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

ProMIS Neurosciences's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.03/0.09
=11.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of ProMIS Neurosciences was 12.01. The lowest was 0.49. And the median was 3.18.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


ProMIS Neurosciences Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ProMIS Neurosciences Business Description

Industry
Traded in Other Exchanges
Address
1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
Executives
Madge K. Shafmaster director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Patrick D. Kirwin director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Larry Douglas Altstiel officer: Chief Medical Officer C/O NEUROTROPE, INC., 50 PARK PLACE, SUITE 1401, NEWARK NJ 07102
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Jeremy M. Sclar 10 percent owner 33 BOYLSTON STREET, SUITE 3000, CHESTNUT HILL MA 02467
Gail M Farfel director, officer: Chief Executive Officer 142 TEMPLE STREET, SUITE 205, NEW HAVEN CT 06510
Max A. Milbury officer: Principal Accounting Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Gavin T. Malenfant officer: Chief Operating Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Neil Cashman director, officer: Chief Scientific Officer C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Johanne Kaplan officer: Chief Development Officer PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Eugene Williams director, officer: Chairman and CEO C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
Richard J. Gregory director 830 WINTER STREET, WALTHAM MA 02451
Neil K Warma director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2
William W Wyman director 4 N. BALCH STREET, HANOVER NH 03755
Josh Mandel-brehm director C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO A6 M4S 3E2

ProMIS Neurosciences Headlines